Daily Roundup

Arena REIT lifts FY2027 distribution guidance to 20 cents per security, marking a 3.9% increase from the prior year. The updated forecast sits towards the top of the range flagged to markets back in October and reflects solid progress in unwinding the company's Edge Early Learning portfolio. Arena has also locked in two additional early learning centre property sales this month, bringing total FY2027 sale proceeds to $23.1 million—a healthy 7.9% premium to book value. The guidance assumes all announced Edge transactions secure necessary approvals and lease assignments, with no new acquisitions or material shifts in market conditions on the horizon.

Over in the regenerative medicine space, Orthocell's strategic partner Marine Biomedical has secured FDA clearance for PearlBone, a marine-derived bone graft substitute that opens the door to the U.S. market. Orthocell holds a 12% stake in Marine Biomedical following a A$1.05 million investment and has locked in first right of refusal over global distribution rights for the product and future bone repair offerings. The clearance represents a meaningful milestone for both companies and positions PearlBone to tap into the considerable potential of the global bone repair and regeneration market.

Power Minerals is back in action after securing a game-changing A$5 million strategic investment from Critical Metals Corp, the Nasdaq-listed company behind European Lithium. The capital will fund exploration work at Power Minerals' high-grade Morro do Ferro rare earth project in Brazil, with Critical Metals set to hold approximately 8% of the company upon completion. The investment lifts Power Minerals back to quotation following a trading suspension and provides strategic exposure to the project while bolstering the company's access to international funding and development pathways.

Viking Mines is making headway on its Linka Tungsten Project in Nevada, with drilling confirming high-grade mineralisation both above and below historical workings. Metallurgy testwork has delivered encouraging results—a 56.9% WO3 scheelite concentrate at 76.0% recovery—supporting a conventional processing approach. The company is evaluating multiple processing pathways, including modular facilities and toll-treatment options, while permitting studies advance toward a late 2027 mining permit application. Growth potential is also being explored through additional feed sources and regional targets as Viking works toward a potential tungsten production restart.

Clever Culture Systems has locked in $2.6 million in funding to develop APAS® Revolution, a new benchtop configuration of its Automated Plate Assessment System designed for smaller pharmaceutical manufacturers. The move is expected to expand the addressable market by roughly 50% to $4.3 billion, tapping into facilities currently without an automation solution. The funding package combines a $1.0 million capital raise with a $1.6 million unsecured loan due November 2027, and the company expects the new product to deliver payback in under two years from launch.